中国国家药品监督管理局药品审评中心(CDE)最新公示,安进(Amgen)公司的1类新药AMG 570获得一项临床试验默示许可,拟开发治疗系统性红斑狼疮(SLE)。公开资料显示,AMG 570是一款靶向BAFF和ICOSL的双特异性抗体,全球范围内正处于2期临床研究阶段。 截图来源:CDE官网 系统性红斑狼疮是一种临床表现为多系统损害症状的慢性系...
By targeting both BAFF and ICOSL, AMG 570 has the potential to achieve a large treatment effect size in autoimmune diseases such as SLE and rheumatoid arthritis. Disclosure of Interest H. Hsu Shareholder of: Amgen, M. Zhang Shareholder of: Amgen, K. Miner Shareholder of: Amgen, G. Kevin ...
doi:10.1136/lupus-2019-lsm.290Background Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. AMG 570 is a bispecific molecule targeting T cell and B cell activity through inhibition of inducible costimulator ligand (ICOSL)...
Background/Purpose Current SLE treatment options have limited efficacy and potential toxicities that impede an individual's ability to remain on therapy. AMG 570 is a bispecific antibody inhibiting both ICOSL and BAFF that engages ICOSL on antigen-presenting cells (dendritic cells and B cells) and ...